RecruitingNot ApplicableNCT07256119

Evaluation of the Effect of Alpha Lipoic Acid on Radiation Induced Dermatitis in Breast Cancer Patients


Sponsor

Ain Shams University

Enrollment

40 participants

Start Date

Aug 6, 2024

Study Type

INTERVENTIONAL

Conditions

Summary

the purpose of this study is to evaluate the Effect of Alpha Lipoic Acid on Radiation Induced Dermatitis in Breast Cancer Patients


Eligibility

Sex: FEMALEMin Age: 18 YearsMax Age: 75 Years

Plain Language Summary

Simplified for easier understanding

This study tests whether alpha lipoic acid — a naturally occurring antioxidant supplement — can reduce radiation-related skin damage (called radiation dermatitis) in women receiving radiotherapy for early-stage breast cancer. **You may be eligible if...** - You are a woman aged 18 or older - You have been diagnosed with early-stage invasive breast cancer - You are scheduled to receive adjuvant radiotherapy (40 Gy over 15 sessions) **You may NOT be eligible if...** - You have had radiotherapy before - You have inflammatory breast cancer or metastatic (spread) breast cancer - You have conditions that affect radiation skin response Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DIETARY_SUPPLEMENTAlpha Lipoic Acid

alpha lipoic acid 300 mg three times daily under the trade name of THIOTACID manufactured by EVAPHARMA.


Locations(1)

Zagazig University Hospitals

Zagazig, Egypt

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07256119


Related Trials